Downregulation of PD-L1 expression by Wnt pathway inhibition to enhance PD-1 blockade efficacy in hepatocellular carcinoma

被引：0
|
作者：
Yu-Yun Shao [1 ]
Han-Yu Wang [3 ]
Hung-Wei Hsu [4 ]
Rita Robin Wo [3 ]
Ann-Lii Cheng [3 ]
Chih-Hung Hsu [3 ]
机构：
[1] National Taiwan University College of Medicine,Graduate Institute of Oncology
[2] National Taiwan University College of Medicine,Department of Internal Medicine
[3] National Taiwan University Hospital,Department of Oncology
[4] National Taiwan University Cancer Center,Department of Medical Oncology
来源：
Biology Direct | / 20卷 / 1期
关键词：
Beta-catenin; Hepatocellular carcinoma; Immunotherapy; Programmed death-ligand 1; Tankyrase; Wnt pathway;
D O I：
10.1186/s13062-025-00645-8
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Mechanisms of Resistance to PD-1 and PD-L1 Blockade
    Nowicki, Theodore S.
    Hu-Lieskovan, Siwen
    Ribas, Antoni
    CANCER JOURNAL, 2018, 24 (01): : 47 - 53
  • [22] Targeting the PD-1/PD-L1 Pathway in Renal Cell Carcinoma
    Kammerer-Jacquet, Solene-Florence
    Deleuze, Antoine
    Saout, Judikael
    Mathieu, Romain
    Laguerre, Brigitte
    Verhoest, Gregory
    Dugay, Frederic
    Belaud-Rotureau, Marc-Antoine
    Bensalah, Karim
    Rioux-Leclercq, Nathalie
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (07)
  • [23] The efficacy of PD-1/PD-L1 blockade in cold cancers and future perspectives
    Majidpoor, Jamal
    Mortezaee, Keywan
    CLINICAL IMMUNOLOGY, 2021, 226
  • [24] NEK2 Inhibition Enhances the Efficacy of PD-1/PD-L1 Blockade in Multiple Myeloma
    Cheng, Yan
    Sun, Fumou
    Cao, Huojun
    Gai, Dongzheng
    Peng, Bailu
    Xu, Hongwei
    Rhee, Fritsvan
    Janz, Siegfried
    Tricot, Guido
    Shaughnessy, John D., Jr.
    Zhan, . Fenghuang
    BLOOD, 2021, 138
  • [25] Beyond inhibition against the PD-1/PD-L1 pathway: development of PD-L1 inhibitors targeting internalization and degradation of PD-L1
    Guo, Jiazheng
    Yu, Fengyi
    Zhang, Kuojun
    Jiang, Sheng
    Zhang, Xiangyu
    Wang, Tianyu
    RSC MEDICINAL CHEMISTRY, 2024, 15 (04): : 1096 - 1108
  • [26] Efficacy of targeted therapies after PD-1/PD-L1 blockade in metastatic renal cell carcinoma
    Albiges, Laurence
    Fay, Andre P.
    Xie, Wanling
    Krajewski, Katherine
    McDermott, David F.
    Heng, Daniel Y. C.
    Dariane, Charles
    DeVelasco, Guillermo
    Lester, Renee
    Escudier, Bernard
    Choueiri, Toni K.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 (17) : 2580 - 2586
  • [27] Predictive role of PD-L1 expression in the response of renal Medullary carcinoma to PD-1 inhibition
    Sodji, Quaovi
    Klein, Kandy
    Sravan, Kavuri
    Parikh, Jigarkumar
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [28] Clinical outcomes and influencing factors of PD-1/PD-L1 in hepatocellular carcinoma
    Wang, Jiting
    Li, Jun
    Tang, Guiju
    Tian, Yuan
    Su, Song
    Li, Yaling
    ONCOLOGY LETTERS, 2021, 21 (04) : 1 - 8
  • [29] PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
    Li, Qian
    Han, Jingjing
    Yang, Yonglin
    Chen, Yu
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [30] Expression and prognostic value of PD-1 and PD-L1 in colorectal carcinoma
    Aouadi, R.
    Helal, I.
    Khanchel, F.
    Hedhli, R.
    Ben Brahim, E.
    Jouini, R.
    Debbiche, A. Chadli
    VIRCHOWS ARCHIV, 2024, 485 : S151 - S152
12345